Entecavir Monohydrate (Entecavir Hydrate) CAS No.: 209216-23-9
Active Pharmaceutical Ingredients 2025-03-03
Molecular Formula: C12H17N5O4
Molecular Weight: 295.294
CAS No.: 209216-23-9
It is a new type of cyclopentylguanosine anti HBV drug. Its pharmacological action is similar to that of entecavir. It is clinically suitable for the treatment of chronic hepatitis B virus inflammation with active replication of the virus, continuous elevation of serum aminotransferase ALT or liver histology showing active lesions.
Description
It is white or almost white powder, odorless, practically insoluble in water, in anhydrous ethanol and in heptanes, slightly soluble in methanol.
Application
It is a new type of cyclopentylguanosine anti HBV drug. Its pharmacological action is similar to that of entecavir. It is clinically suitable for the treatment of chronic hepatitis B virus inflammation with active replication of the virus, continuous elevation of serum aminotransferase ALT or liver histology showing active lesions.
It is guanine nucleoside analogue, which has an inhibitory effect on hepatitis B virus (HBV) polymerase.
Entecavir has a strong antiviral ability and low incidence of drug resistance in long-term use. It can effectively treat chronic hepatitis B, and its curative effect is better than that of lamivudine.
The resistance rate of entecavir was 0 in the first year of treatment, but it was 5.8% in the first year of treatment in patients with YMDD mutation.
Packing
25kgs / drum
Storage：
Keep the container sealed and store in a cool and ventilated warehouse. The temperature of the warehouse should not exceed 37 ℃.
Shelf Life :
24 months from date of production when stored in good condition.
Minimum Order
One package.
Introduction to Entecavir Hydrate
| Attribute | Details |
|---|---|
| Definition | Entecavir hydrate is a nucleoside analog and a guanine derivative, specifically a monohydrate form of entecavir, used as an antiviral drug for the treatment of chronic hepatitis B infection. |
| Mechanism of Action | It inhibits the activity of hepatitis B virus (HBV) DNA polymerase (reverse transcriptase) by competing with the natural substrate, deoxyguanosine triphosphate, and inhibits all three activities of the viral polymerase: initiation of viral DNA synthesis, reverse transcription of the pregenomic mRNA to form the negative strand of viral DNA, and synthesis of the positive strand of viral DNA. |
| Clinical Use | Entecavir hydrate is indicated for the treatment of chronic hepatitis B in adults with active viral replication, elevated serum alanine aminotransferase (ALT) levels, or histologically active liver disease. |
Entecavir hydrate is an effective antiviral agent for managing chronic hepatitis B infections by inhibiting viral DNA synthesis and replication. Its clinical applications are well-established for patients with active viral replication and liver disease.
